ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Adalimumab

Also written as “adalimumab”, “MSB11022” and “M923”.

Its studies are mostly in Arthritis, Rheumatoid · Psoriasis · Crohn Disease · Colitis, Ulcerative · Hidradenitis Suppurativa, led by 17 companies.

Drug pageAdalimumab: every studyMany companies study it; this page follows only the 149 they lead. All 319 studies, academic ones too, with its approvals and label.
Furthest: phase 4, since Sep 13, 2005149 company-led studies, 7 open or runningNext primary completion: Jun 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Abbottits history only620 open or runningphase 4since Sep 13, 2005Nov 1, 2002none ahead
AbbVie543 open or runningphase 4since May 25, 2010Sep 13, 2005Sep 2027phase 2 · NCT06257875
Alvotech Swissits history only60 open or runningphase 3since Feb 5, 2019Jun 8, 2018none ahead
Johnson & Johnsonits history only50 open or runningphase 3since Dec 18, 2013Dec 18, 2013none ahead
Fresenius Kabiits history only40 open or runningphase 3since Jan 17, 2016Jan 17, 2016none ahead
Biocadits history only30 open or runningphase 3since Mar 31, 2016Mar 16, 2015none ahead
Cinnagenits history only20 open or runningphase 3since May 24, 2017May 24, 2017none ahead
Sino Biopharmaceuticalits history only22 open or runningphase 4since Apr 8, 2026Apr 8, 2026Apr 2028phase 4 · NCT07529925
Takedaits history only20 open or runningphase 4since May 5, 2016Mar 15, 2015none ahead
Viatrisits history only20 open or runningphase 3since Nov 9, 2015Jun 3, 2015none ahead

Also a collaborator on its studies: Merck KGaA, Darmstadt, Germany, Mylan, Pharm-Olam, PPD DEVELOPMENT, LP, PRA Health Sciences, IST GmbH, Germany, Parexel, Pivotal S.L., GlaxoSmithKline, Regeneron Pharmaceuticals, Eisai and Abbott Japan.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of AbbVie only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). An open circle marks the day WHO proposed its name. Dates ahead are the sponsors’ estimates.

Before these, 37 studies since Sep 13, 2005.

  1. Jul 7, 20142 phase 3 studiesNCT02185014, NCT02196701
  2. Jul 22, 2014Phase 4 study in Arthritis, RheumatoidNCT02198651 · 149 enrolled · United States, Australia, Austria and more
  3. Jul 14, 2015Phase 3 study in Crohn DiseaseNCT02499783 · 205 enrolled
  4. Aug 20, 2015Phase 3 study in PsoriasisNCT02533375 · 10 enrolled
  5. Dec 10, 20152 phase 3 studiesNCT02629159, NCT02632175
  6. Jun 20, 20162 phase 4 studiesNCT02808975, NCT02814175
  7. Sep 7, 2016Phase 4 study in Axial SpondyloarthritisNCT02897115 · 22 enrolled
  8. Sep 14, 2016Phase 3 study in Hidradenitis SuppurativaNCT02904902 · 15 enrolled · Japan
  9. Oct 12, 2017Phase 3 study in Pyoderma GangrenosumNCT03311464 · 22 enrolled · Japan
  10. Dec 9, 2017Named adalimumabINNProposed as its International Nonproprietary Name in WHO's List 118 · before, MSB11022, M923
  11. Jan 29, 2019Phase 2 study in Arthritis, RheumatoidNCT03823391 · 48 enrolled · United States, Germany, Hungary and more
  12. Jun 8, 2022Phase 4 study in Non-infectious Intermediate Posterior- or Pan-uveitisNCT05414201 · 87 enrolled · China
  13. Apr 4, 2023Phase 3 study in Arthritis, RheumatoidNCT05814627 · 487 enrolled · United States, Argentina, Belgium and more
  14. Oct 2, 2023Phase 2 study in Colitis, UlcerativeNCT06257875 · 156 enrolled · United States, Australia, Austria and more
  15. Oct 20, 2023Phase 3 study in Arthritis, JuvenileNCT06100744 · 40 planned · United States, Australia, Canada and more

Ahead

  1. Sep 2027Primary completion: phase 2 study in Colitis, UlcerativeNCT06257875

TargetBeta

TNF →read by rule
“TNF-alpha inhibitor”ChEMBL 37, by rule

Other programs on TNF

ProgramCompanyFurthest phaseStudies
Brentuximab VedotinrulePfizerphase 437
CHS-1420rulenanjing-king-friend-biochemical-pharmaceutical-co-ltdphase 32
brivekimigSanofiphase 26
Hadlimarulebiora-therapeutics-incphase 11

Studies

All 54 AbbVie leads, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06100744Arthritis, Juvenile · United States, Australia, Canada and more3RecruitingSep 202640
NCT06257875Colitis, Ulcerative · United States, Australia, Austria and more2Active, not recruitingSep 2027156
NCT05814627Arthritis, Rheumatoid · United States, Argentina, Belgium and more3CompletedJul 15, 2026487
NCT05414201Non-infectious Intermediate Posterior- or Pan-uveitis · China4CompletedJun 10, 202487
NCT03823391Arthritis, Rheumatoid · United States, Germany, Hungary and more2CompletedApr 8, 202048
NCT03311464Pyoderma Gangrenosum · Japan3CompletedAug 20, 201922
NCT02904902Hidradenitis Suppurativa · Japan3CompletedSep 1, 201715
NCT02897115Axial Spondyloarthritis4TerminatedDec 21, 201722
NCT02814175Arthritis, Psoriatic · United States, Australia, Brazil and more4CompletedSep 23, 2019246
NCT02808975Hidradenitis Suppurativa · United States, Belgium, Canada and more4CompletedMay 16, 2019206
NCT02632175Colitis, Ulcerative · United States, Japan, Poland and more3CompletedApr 8, 202559
NCT02629159Arthritis, Rheumatoid · United States, Argentina, Australia and more3Active, not recruitingOct 27, 20171,629
NCT02533375Psoriasis3CompletedSep 15, 201610
NCT02499783Crohn Disease3CompletedMay 19, 2017205
NCT02198651Arthritis, Rheumatoid · United States, Australia, Austria and more4CompletedMay 3, 2018149
NCT02196701Psoriasis3CompletedMar 17, 201746
NCT02185014Crohn Disease3CompletedNov 3, 2017252
NCT02148718Crohn Disease4CompletedAug 2016100
NCT02065622Colitis, Ulcerative · United States, Austria, Belgium and more3CompletedSep 5, 2019952
NCT02065570Crohn Disease · United States, Austria, Belgium and more3CompletedJan 30, 2020514
NCT02065557Colitis, Ulcerative · United States, Australia, Austria and more3CompletedFeb 7, 2020101
NCT02016482Nail Psoriasis3CompletedOct 2015217
NCT02015793Crohn Disease2CompletedFeb 201530
NCT01958827Crohn Disease3CompletedMar 201528
NCT01808118Axial Spondyloarthritis3CompletedFeb 21, 2017673
NCT01752855Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more2CompletedOct 201388
NCT01646073Psoriasis · China3CompletedDec 2013425
NCT01712178Arthritis, Rheumatoid · United States, Belgium, Czech Republic and more2CompletedMay 2013100
NCT01644396Moderate to Severe Plaque Psoriasis · Russian Federation4CompletedSep 201350
NCT01561313Arthritis, Rheumatoid · Belgium, Czech Republic2CompletedNov 201264
NCT01550965Colitis, Ulcerative3CompletedApr 2015463
NCT01635764Hidradenitis Suppurativa3CompletedAug 2016508
NCT01502423Arthritis, Rheumatoid · Australia, Canada, Germany2CompletedNov 201261
NCT01468233Hidradenitis Suppurativa3CompletedApr 2014326
NCT01468207Hidradenitis Suppurativa3CompletedJan 2014307
NCT01265823Psoriasis · Mexico4CompletedFeb 2012150
NCT01251614Plaque Psoriasis3CompletedDec 2013114
NCT01243671Intestinal Behçet's Disease · Japan3CompletedMar 201220
NCT01235689Crohn Disease3CompletedNov 3, 2016252
NCT01185301Arthritis, Rheumatoid · United States, Argentina, Austria and more3CompletedSep 2012395
NCT01185288Arthritis, Rheumatoid · United States, Puerto Rico4CompletedJan 2013309
NCT01166282Arthritis, Juvenile3CompletedNov 201246
NCT01162421Arthritis, Rheumatoid4CompletedJul 201577
NCT01148225Uveitis3CompletedMay 21, 2018424
NCT01138657Uveitis3CompletedJul 2014239
NCT01124838Uveitis3CompletedMay 2015261
NCT01064856Peripheral Spondyloarthritis3CompletedAug 2011165
NCT00939003Axial Spondyloarthritis · United States, Australia, Belgium and more3CompletedFeb 2011192
NCT00853099Colitis, Ulcerative · Japan3CompletedMay 2011274
NCT00775437Arthritis, Juvenile3CompletedMar 201332
NCT00686374Crohn Disease3CompletedApr 4, 2017100
NCT00650156Arthritis, Rheumatoid · China1CompletedOct 200724
NCT00573794Colitis, Ulcerative3CompletedDec 2016592
NCT00195663Arthritis, Rheumatoid · United States, Australia, Austria and more3CompletedApr 2004799

How it is read

Names in the registry

  • “Adalimumab”, 69 entries
  • “adalimumab”, 63 entries
  • “MSB11022”, 3 entries
  • “M923”, 3 entries
  • “Humira (adalimumab)”, 3 entries

Codes read as this program: AVT02.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.